Followers | 7 |
Posts | 1577 |
Boards Moderated | 0 |
Alias Born | 02/27/2014 |
Saturday, February 07, 2015 2:19:33 AM
Musclepharm numbers were not too encouraging for q3, but Musclepharm did buy it's stock back at $10 in the beginning of q4 though....that is worth to remember. Also, more than halfway into q4, Musclepharm didn't promise too much bottom line in q4, but believed in it's revenue.
Actually, Musclepharm was so satisfied with revenue that it didn't even bother to promote it's products aggressively during the holidays.
That shows that Musclepharm does care about margins and that Musclepharm does try not to lose too much money.
I think this was the beginning to a shift where Musclepharm tries to incentivize employees to improve capital return and maximize profits over revenue growth at any cost.
Musclepharm is getting more conservative, and it is striving to grow revenues towards critical mass levels in q1 or q2 with the aim to become profitable, and not just to impress investors with higher revenue numbers.
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM